CRISPR screening is proving to be a robust platform for the identification and validation of new biological targets for disease treatment. It is hoped that CRISPR screens will accelerate drug development by providing more robust targets for validation than siRNA screens, for example.
Much progress has been made in carrying out CRISPR screens cell lines, often with proliferation based readouts, but these may not fully recapitulate physiologic cell behavior or produce comprehensive data in all experimental circumstances. Horizon has developed CRISPR screening capabilities in several more complex models and biologies including primary immune cells and organoids, and has extended the screening pipeline with technologies such as single-cell analysis, which should aid in identifying more physiologically relevant targets.
This webinar will cover in detail the development of CRISPR screens in several of these more complex biological backgrounds. Further, we will present information on use of some of our recent CRISPR products in these cell types.
